Transcatheter mitral valve repair in patients with CKD
- PMID: 35523958
- DOI: 10.1038/s41581-022-00583-y
Transcatheter mitral valve repair in patients with CKD
Comment on
-
Impact of baseline renal dysfunction on cardiac outcomes and end-stage renal disease in heart failure patients with mitral regurgitation: the COAPT trial.Eur Heart J. 2022 May 1;43(17):1639-1648. doi: 10.1093/eurheartj/ehac026. Eur Heart J. 2022. PMID: 35134897 Clinical Trial.
References
-
- Beohar, N. et al. Impact of baseline renal dysfunction on cardiac outcomes and end-stage renal disease in heart failure patients with mitral regurgitation: the COAPT trial. Eur. Heart J. ehac026 (2022).
-
- Stone, G. W. et al. Transcatheter mitral-valve repair in patients with heart failure. N. Engl. J. Med. 379, 2307–2318 (2018). - DOI
-
- Obadia, J.-F. et al. Percutaneous repair or medical treatment for secondary mitral regurgitation. N. Engl. J. Med. 379, 2297–2306 (2018). - DOI
-
- Sawalha, K. et al. Impact of chronic kidney disease on in-hospital outcomes and readmission rate after edge-to-edge transcatheter mitral valve repair. Catheter. Cardiovasc. Interv. 97, E569–E579 (2021). - DOI
-
- Dave, P. et al. The effect of transcatheter mitral valve repair on short-term mortality in patients with chronic kidney disease — a systematic review and meta-analysis. Cardiovasc. Revasc. Med. 30, 78–84 (2021). - DOI
Publication types
MeSH terms
Grants and funding
LinkOut - more resources
Full Text Sources
Medical
